Epinephrine is under clinical development by ARS Pharmaceuticals and currently in Phase I for Infectious Rhinitis. According to GlobalData, Phase I drugs for Infectious Rhinitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Epinephrine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epinephrine overview
Epinephrine (ARS-1) is under development for the treatment of anaphylaxis caused by severe allergic reactions to medications, insect bites, asthma, urticaria, seasonal allergic rhinitis, food allergy and infectious rhinitis. It is formulated as spray and administered through intranasal route. The drug candidate acts by targeting ADRA, ADRB adrenergic receptors. It is developed based on Intravail technology.
ARS Pharmaceuticals overview
ARS Pharmaceuticals (ARS Pharma) is a biopharmaceutical company that develops the treatments for severe allergic reactions. The company’s main product in development is a needle-free, low-dose intranasal epinephrine nasal spray intended for use as a rescue medication for people with Type 1 severe allergic reactions, including anaphylaxis. Its products include neffy. ARS Pharma’s products are designed for patients and caregivers that need a safe, effective, and easy-to-administer alternative to injectable devices. It serves customers across the US. ARS Pharma is headquartered in San Diego, California, the US.
For a complete picture of Epinephrine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
